Document is current

Article History

Received: 4 September 2024

Accepted: 19 September 2024

First Online: 4 October 2024

Declarations

:

: Thanin Asawavichienjinda received honoraria for lectures and educational events from Novartis (Thailand) Ltd., Zuellig Pharma Ltd., DKSH (Thailand) Ltd., B.L. HUA & Co., Ltd., and Pfizer (Thailand) Ltd. and support for attending meetings and/or travel from Novartis (Thailand) Ltd., Zuellig Pharma Ltd., DKSH (Thailand) Ltd., and B.L. HUA & Co., Ltd. Nutchawan Jittapiromsak has no disclosures at this time. Andrew Blumenfeld's disclosures are the following: Advisory Board: Allergan, Aeon, Alder, Amgen, Biohaven, Lilly, Lundbeck, Novartis, Pfizer, Revance, Teva, Theranica, Tonix. Speaker: Allergan, Abbvie, Lilly, Lundbeck, Teva, Theranica. Consultant: Aeon, Allergan, Alder, Amgen, Axon, Biohaven, Lilly, Lundbeck, Pfizer, Novartis, Teva, Theranica, Tonix. Grant support: Aeon, Allergan, Abbvie, Amgen, Lundbeck, Revance. Contributing author: Abbvie, Aeon, Allergan, Amgen, Biohaven, Lilly, Lundbeck, Novartis, Teva, Theranica. Stock options: Haven Health Inc., Aeon, Axon. Andrew Blumenfeld is an Editorial Board member of Pain and Therapy journal. Andrew Blumenfeld was not involved in the selection of peer reviewers for the manuscript or any of the subsequent editorial decisions.

: This case report was reviewed and approved by the Chulalongkorn Institutional Review Board (IRB No. 437/67). The patient provided written informed consent to disclose this information, and consent was obtained for publication of potentially identifiable information. The data were retrieved from the patient’s electronic medical record and logbook headache diary.